Premium
Adverse effects of a single dose of (+)‐sotalol in patients with mild stable asthma
Author(s) -
Devereux G.,
Fishwick K.,
Aiken T. C.,
Bourke S. J.,
Hendrick D. J.
Publication year - 1998
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1998.00039.x
Subject(s) - sotalol , medicine , placebo , asthma , heart rate , anesthesia , airway , cardiology , blood pressure , atrial fibrillation , alternative medicine , pathology
Aims To investigate the effect of (+)‐sotalol, which is not thought to possess clinically significant β‐adrenoceptor blocking activity, on airway responsiveness in subjects with mild asthma.Methods A placebo controlled, double‐blind, single dose, cross over study, evaluating the effects of oral (+)‐sotalol 300 mg and oral (±)‐sotalol 240 mg, on airway responsiveness, FEV 1 , and heart rate in 18 asthmatic volunteers with quantifiable levels of airway responsiveness.Results Compared with placebo, (+)‐sotalol induced a significant increase in airway responsiveness, and a significant decrease in FEV 1 , but there was no significant change in heart rate. Following (±)‐sotalol there was no significant effect on airway responsiveness, but there were significant decreases in FEV 1 and heart rate. In one subject both (+)‐sotalol and (±)‐sotalol provoked a 49% decrement in FEV 1 , and in another there were decrements of 20% and 18%, respectively.Conclusions Despite theoretical considerations, it cannot be assumed that (+)‐sotalol is safe in patients with asthma.